Apitolisib(GDC-0980,RG7422) is a dual PI3K/mTOR inhibitor.GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.
For research use only. We do not sell to patients.